文献速递消化系统肿瘤

抗EGFR耐药克隆在进展后呈指数衰减:对抗EGFR再挑战的启示

Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge.
PubMed 文献 · Ann Oncol · 2019-01-01

本研究分析135例RAS/BRAF野生型转移性结直肠癌患者接受抗EGFR治疗期间获得RAS和/或EGFR突变后的进展后循环肿瘤DNA谱,发现RAS和EGFR相对突变等位基因频率呈指数衰减,累积半衰期为4.4个月,外部验证数据集73例确认半衰期4.3个月;另一回顾性队列80例显示再挑战治疗间隔时间延长后总缓解率更高。

要点

  • RAS和EGFR相对突变等位基因频率在停用抗EGFR后呈指数衰减,累积半衰期为4.4个月。
  • 外部验证数据集73例确认指数衰减,估计半衰期为4.3个月。
  • 回顾性队列80例显示再挑战治疗间隔延长后总缓解率更高,与模型预测一致。

核心结论

  • 这些结果为抗EGFR再挑战提供了科学支持,并指导再挑战启动的最佳时机。

研究设计与样本

  • 研究分析了135例RAS/BRAF野生型转移性结直肠癌患者接受抗EGFR治疗期间获得RAS和/或EGFR突变后的进展后循环肿瘤DNA谱。
  • 验证队列为外部数据集73例,其循环肿瘤DNA谱提示既往抗EGFR暴露并有连续采样。
  • 另用一回顾性队列80例评估再挑战治疗期间的总缓解率和无进展生存期。

主要发现

  • RAS和EGFR相对突变等位基因频率呈指数衰减,RAS的r2=0.93,EGFR的r2=0.94,累积半衰期为4.4个月。
  • 外部验证数据集73例确认指数衰减,估计半衰期为4.3个月。
  • 回顾性队列80例显示,随着再挑战治疗间隔时间延长,患者的总缓解率更高,与模型预测一致。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Colorectal cancer (CRC) has been shown to acquire RAS and EGFR ectodomain mutations as mechanisms of resistance to epidermal growth factor receptor (EGFR) inhibition (anti-EGFR). After anti-EGFR withdrawal, RAS and EGFR mutant clones lack a growth advantage relative to other clones and decay; however, the kinetics of decay remain unclear. We sought to determine the kinetics of acquired RAS/EGFR mutations after discontinuation of anti-EGFR therapy. PATIENTS AND METHODS: We present the post-progression circulating tumor DNA (ctDNA) profiles of 135 patients with RAS/BRAF wild-type metastatic CRC treated with anti-EGFR who acquired RAS and/or EGFR mutations during therapy. Our validation cohort consisted of an external dataset of 73 patients with a ctDNA profile suggestive of prior anti-EGFR exposure and serial sampling. A separate retrospective cohort of 80 patients was used to evaluate overall response rate and progression free survival during re-challenge therapies. RESULTS: Our analysis showed that RAS and EGFR relative mutant allele frequency decays exponentially (r2=0.93 for RAS; r2=0.94 for EGFR) with a cumulative half-life of 4.4 months. We validated our findings using an external dataset of 73 patients with a ctDNA profile suggestive of prior anti-EGFR exposure and serial sampling, confirming exponential decay with an estimated half-life of 4.3 months. A separate retrospective cohort of 80 patients showed that patients had a higher overall response rate during re-challenge therapies after increasing time intervals, as predicted by our model. CONCLUSION: These results provide scientific support for anti-EGFR re-challenge and guide the optimal timing of re-challenge initiation.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Parseghian CM, Loree JM, Morris VK, et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2019. PMID: 30462160. doi:10.1093/annonc/mdy509

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。